NEUP revenueFY2026$1.17M
- FY YoY
- -92.5%
NEUP revenue was $1.17M for fiscal 2026 (ended Jun 30, 2026), down 92.5% from fiscal 2025.
Neuphoria Therapeutics Inc. (NEUP) financials
For fiscal 2026 (ended Jun 30, 2026), Neuphoria Therapeutics Inc. reported $1.17M of revenue and -$13.45M of net income.
- Revenue, FY2026
- $1.17M
- Revenue growth, YoY
- -92.5%
- Net income, FY2026
- -$13.45M
- Net margin
- -1145.7%
- EPS, diluted, FY2026
- -$3.06
- Cash
- $19.87M
- P/S
- 12.81
- Market cap
- $15.0M
FY2025FY2026
FY2023FY2026
NEUP revenue and earnings growth
NEUP net incomeQ4 2026-$4.90M
NEUP net income was -$4.90M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$8.88M a year earlier. For the full fiscal 2026 it was -$13.45M, compared with -$369.6K in fiscal 2025.
NEUP EPSFY2026-$3.06
NEUP diluted EPS was -$3.06 for fiscal 2026 (ended Jun 30, 2026).
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Revenue | $1.17M | $15.65M | - | - |
| Research and development | - | $9.01M | $9.42M | $13.07M |
| Selling, general and admin | $7.44M | $7.77M | $8.47M | $8.91M |
| Operating income | -$16.45M | -$1.13M | -$17.89M | -$21.98M |
| Pre-tax income | -$13.59M | -$838.0K | -$15.58M | -$21.52M |
| Income tax | -$139.2K | -$468.4K | -$87.3K | -$139.2K |
| Net income | -$13.45M | -$369.6K | -$15.49M | -$21.38M |
| EPS, basic | -$3.06 | -$0.23 | -$18.62 | -$0.02 |
| EPS, diluted | -$3.06 | -$0.23 | -$18.62 | -$0.02 |
| Diluted shares | 4.4M | 1.6M | 832,225 | 1.47B |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $19.87M | $14.21M | $12.69M | $12.18M |
| Receivables | $813.4K | $11.9K | $126.9K | $426.1K |
| Current assets | $21.07M | $15.04M | $13.19M | $13.33M |
| Goodwill | $3.50M | $8.64M | $8.69M | $8.69M |
| Total assets | $28.71M | $28.59M | $27.65M | $28.56M |
| Current liabilities | $756.6K | $4.22M | $3.83M | $2.74M |
| Total liabilities | $4.11M | $9.59M | $10.16M | $6.55M |
| Shareholders' equity | $24.60M | $19.00M | $17.49M | $22.01M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Operating cash flow | -$12.35M | $77.2K | -$14.68M | -$14.64M |
| Financing cash flow | $17.92M | $1.53M | $15.11M | $3.86M |
| Stock-based compensation | $351.6K | $163.8K | $814.8K | $1.35M |
| Depreciation and amortization | $663.0K | $662.9K | $663.0K | $663.2K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | -$13.3K | $15.00M | $662.7K | $0 | - | - | - | - |
| Research and development | - | - | $697.7K | $3.79M | $3.75M | $1.62M | $1.74M | $1.90M | $3.10M | $1.20M | $2.03M | $3.09M |
| Selling, general and admin | $1.76M | $1.69M | $2.13M | $1.87M | $2.07M | $1.41M | $2.63M | $1.67M | $2.38M | $1.20M | $2.52M | $2.38M |
| Operating income | -$5.53M | -$1.21M | -$4.06M | -$5.65M | -$5.84M | $11.98M | -$3.70M | -$3.57M | -$5.48M | -$2.39M | -$4.55M | -$5.47M |
| Pre-tax income | -$4.94M | -$539.9K | $1.83M | -$9.94M | -$9.15M | $11.18M | -$1.93M | -$937.0K | -$2.72M | -$2.76M | -$4.59M | -$5.51M |
| Income tax | -$34.8K | -$34.8K | -$34.8K | -$34.8K | -$266.6K | -$81.2K | $11.6K | -$132.2K | -$34.1K | $16.4K | -$34.8K | -$34.8K |
| Net income | -$4.90M | -$505.1K | $1.86M | -$9.91M | -$8.88M | $11.26M | -$1.94M | -$804.8K | -$2.69M | -$2.78M | -$4.55M | -$5.47M |
| EPS, basic | - | -$0.09 | $0.41 | -$4.41 | - | $6.55 | -$1.23 | -$0.62 | - | -$2.83 | -$5.31 | $0.00 |
| EPS, diluted | - | -$0.09 | -$0.77 | -$4.41 | - | $6.55 | -$1.79 | -$0.62 | - | -$2.83 | -$5.31 | $0.00 |
| Diluted shares | - | 5.4M | 4.5M | 2.2M | - | 1.7M | 1.6M | 1.3M | - | 981,040 | 857,264 | 1.50B |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.87M | $19.44M | $22.17M | $13.65M | $14.21M | $17.04M | $4.34M | $8.08M | $12.69M | $8.43M | $10.15M | $8.14M |
| Receivables | $813.4K | $1.61M | $1.11M | $1.8K | $11.9K | $24.6K | $35.6K | $116.0K | $126.9K | - | - | - |
| Current assets | $21.07M | $21.66M | $23.39M | $13.95M | $15.04M | $17.09M | $4.40M | $8.43M | $13.19M | - | - | - |
| Goodwill | $3.50M | $8.84M | $8.74M | $8.67M | $8.64M | $8.45M | $8.41M | $8.90M | $8.69M | $8.63M | $8.84M | $8.57M |
| Total assets | $28.71M | $34.81M | $36.60M | $27.34M | $28.59M | $30.71M | $18.17M | $22.92M | $27.65M | - | - | - |
| Current liabilities | $756.6K | $1.51M | $2.59M | $5.12M | $4.22M | $1.55M | $2.13M | $2.55M | $3.83M | - | - | - |
| Total liabilities | $4.11M | $5.39M | $6.90M | $14.83M | $9.59M | $4.72M | $4.42M | $5.85M | $10.16M | - | - | - |
| Shareholders' equity | $24.60M | $29.42M | $29.70M | $12.51M | $19.00M | $26.00M | $13.75M | $17.07M | $17.49M | $17.95M | $19.50M | $17.23M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.21M | -$3.34M | -$6.44M | -$3.79M | -$3.59M | $11.45M | -$3.36M | -$4.43M | -$3.01M | -$3.30M | -$3.95M | -$4.43M |
| Financing cash flow | $0 | $0 | $14.66M | $3.25M | $704.7K | $1.16M | -$111.6K | -$227.3K | $7.12M | $1.75M | $5.63M | $612.5K |
| Stock-based compensation | $76.3K | $70.3K | $93.7K | $111.3K | $98.3K | $19.7K | $19.1K | $26.7K | $107.7K | $17.4K | $557.0K | $132.7K |
| Depreciation and amortization | $165.7K | $165.7K | $165.8K | $165.8K | $165.6K | $165.4K | $166.1K | $165.7K | $165.7K | $165.7K | $165.7K | $165.9K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | 79.8% | -558.8% | - | - | - | - | - |
| Net margin | - | - | - | - | - | 75.1% | -293.2% | - | - | - | - | - |
| Current ratio | 27.85 | 14.31 | 9.04 | 2.72 | 3.56 | 11.01 | 2.06 | 3.30 | 3.45 | - | - | - |
Source: XBRL data Neuphoria Therapeutics Inc. files with the SEC, latest filing dated Sep 18, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NEUP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NEUP | $1.17M | -92.5% | -$13.45M | -1145.7% | $15.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
NEUP FAQ
7 questionsWhat is NEUP revenue?
Neuphoria Therapeutics Inc. (NEUP) reported $1.17M of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 92.5% from the year before.Is NEUP profitable?
No. Neuphoria Therapeutics Inc. reported a net loss of $13.45M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does NEUP have?
Neuphoria Therapeutics Inc. reported $19.87M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is NEUP revenue growing?
Neuphoria Therapeutics Inc.'s revenue changed -92.5% in fiscal 2026, to $1.17M.What is NEUP earnings per share?
Diluted earnings per share were -$3.06 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did NEUP last report financial results?
The latest statements here come from Neuphoria Therapeutics Inc.'s 10-K filed on Sep 18, 2026, covering the period ended Jun 30, 2026.Where does this NEUP financial data come from?
Quantisnow builds these statements from the structured XBRL data Neuphoria Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.